Relationship between the pharmacokinetics and pharmacodynamics of procainamide
- PMID: 954350
- DOI: 10.1002/cpt1976203278
Relationship between the pharmacokinetics and pharmacodynamics of procainamide
Abstract
The kinetics of a measure of pharmcologic effect (prolongation of the QT interval) of procainamide, as well as the kinetics of the plasma concentration, urine excretion, and saliva concentration of the drug were investigated in 14 trials in 4 subjects. A single 500-mg dose was given by rapid intravenous infusion, and frequent subsequent determinations of the above variables were made. A 2-compartment pharmacokinetic model with a third compartment for the saliva was used to fit the plasma, urine, and saliva data simultaneously. Analysis of the data reveals that the kinetics of the drug concentrations in saliva and of the pharmacologic effect are indistinguishable. They both must be considered to be different from those of the drug concentrations in plasma. Thus, in normal individuals under the conditions of this study, saliva concentrations more precisely indicate the time-course of drug at a cardiac site of action, although they do not parallel plasma drug concentrations until 6 hr or more after a rapid intravenous infusion. The following average pharmacokinetic parameters for plasma were found: terminal half-life, 2.9 hr; total clearance, 828 ml/min; renal clearance, 334 ml/min; and steady-state volume of distribution, 180 L. Average distribution pseudoequilbrium half-time (t1/2 alpha) was 5.2 min from an initial volume of distribution of 36.6 L.
Similar articles
-
Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction.J Pharm Sci. 1982 Nov;71(11):1256-9. doi: 10.1002/jps.2600711118. J Pharm Sci. 1982. PMID: 7175718
-
The pharmacokinetics of procainamide in normal subjects using a specific gas chromatographic assay.Res Commun Chem Pathol Pharmacol. 1975 Jun;11(2):173-85. Res Commun Chem Pathol Pharmacol. 1975. PMID: 1153866
-
Procainamide elimination kinetics in pediatric patients.Clin Pharmacol Ther. 1982 Nov;32(5):607-11. doi: 10.1038/clpt.1982.210. Clin Pharmacol Ther. 1982. PMID: 7128001
-
Clinical pharmacokinetics of procainamide.Clin Pharmacokinet. 1978 Mar-Apr;3(2):97-107. doi: 10.2165/00003088-197803020-00001. Clin Pharmacokinet. 1978. PMID: 346289 Review.
-
Clinical pharmacokinetics of N-acetylprocainamide.Clin Pharmacokinet. 1982 May-Jun;7(3):206-20. doi: 10.2165/00003088-198207030-00002. Clin Pharmacokinet. 1982. PMID: 6178545 Review.
Cited by
-
The pharmacokinetics of slow-release procainamide.Eur J Clin Pharmacol. 1978 Dec 1;14(4):261-5. doi: 10.1007/BF00560459. Eur J Clin Pharmacol. 1978. PMID: 729620
-
Biliary elimination of cyclophosphamide in man.Cancer Chemother Pharmacol. 1982;9(1):26-9. doi: 10.1007/BF00296757. Cancer Chemother Pharmacol. 1982. PMID: 7139850
-
Reliability of antiarrhythmic drug plasma concentration monitoring.Clin Pharmacokinet. 1983 Jan-Feb;8(1):63-82. doi: 10.2165/00003088-198308010-00004. Clin Pharmacokinet. 1983. PMID: 6404580 Review.
-
The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II).Clin Pharmacokinet. 1989 Oct;17(4):275-90. doi: 10.2165/00003088-198917040-00005. Clin Pharmacokinet. 1989. PMID: 2686884 Review. No abstract available.
-
The QT interval and cycle length: the influence of atropine, hyoscine and exercise.Br J Clin Pharmacol. 1983 Dec;16(6):615-21. doi: 10.1111/j.1365-2125.1983.tb02230.x. Br J Clin Pharmacol. 1983. PMID: 6661344 Free PMC article.